clinical trial · NCT06671483
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
Takeda·phase3·recruiting·n = 1,088
Psoriatic ArthritisZasocitinibActive ComparatorPlacebo
brief summary
Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.
started
Mar 3, 2025
primary completion
May 18, 2027
completion
Jan 28, 2028
last updated
Apr 6, 2026
official title
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol